Clinical course and outcome of patients with high-level microsatellite instability cancers in a real-life setting: a retrospective analysis.
Clinical course and outcome of patients with high-level microsatellite instability cancers in a real-life setting: a retrospective analysis.
复制标题
DOI：
10.2147/ott.s126905
复制
发表时间：
2017
影响因子：
4
通讯作者：
Hubert A
中科院分区：
文献类型：
--
作者：
Halpern N;Goldberg Y;Kadouri L;Duvdevani M;Hamburger T;Peretz T;Hubert A
高水平微卫星不稳定性（MSI-H）表型在各种恶性肿瘤中的预后和预测意义尚不清楚。我们描述了在现实医院环境中接受治疗的 MSI-H 恶性肿瘤患者的特征、临床病程和结果。对 MSI-H 癌症患者档案进行了回顾性分析。我们分析了遗传数据、临床特征和肿瘤治疗，包括化疗和手术干预。 73 名 MSI-H 癌症患者的临床数据可用。诊断出首次恶性肿瘤的平均年龄为 52.3 岁。八名患者（11%）每人患有四种以上恶性肿瘤。大多数患者（76%）患有结直肠癌（CRC）。 17 名患者 (23%) 仅患有结肠外恶性肿瘤。 18 名女性（36%）患有妇科恶性肿瘤。九名女性 (18%) 患有乳腺癌。平均随访时间为 8.5 年。所有 MSI-H 癌症患者的五年总生存率和无病生存率分别为 86% 和 74.6%。 2期、3期和4期MSI-H CRC患者的五年总生存率分别为89.5%、58.4%和22.9%。尽管MSI-H癌症患者的总体预后良好，但这种优势在晚期MSI-H CRC患者中可能无法维持。
The prognostic and predictive significance of the high-level microsatellite instability (MSI-H) phenotype in various malignancies is unclear. We describe the characteristics, clinical course, and outcomes of patients with MSI-H malignancies treated in a real-life hospital setting. A retrospective analysis of MSI-H cancer patient files was conducted. We analyzed the genetic data, clinical characteristics, and oncological treatments, including chemotherapy and surgical interventions. Clinical data of 73 MSI-H cancer patients were available. Mean age at diagnosis of first malignancy was 52.3 years. Eight patients (11%) had more than four malignancies each. Most patients (76%) had colorectal cancer (CRC). Seventeen patients (23%) had only extracolonic malignancies. Eighteen women (36%) had gynecological malignancy. Nine women (18%) had breast cancer. Mean follow-up was 8.5 years. Five-year overall survival and disease-free survival of all MSI-H cancer patients from first malignancy were 86% and 74.6%, respectively. Five-year overall survival rates of stage 2, 3, and 4 MSI-H CRC patients were 89.5%, 58.4%, and 22.9%, respectively. Although the overall prognosis of MSI-H cancer patients is favorable, this advantage may not be maintained in advanced MSI-H CRC patients.